International Journal of Endocrinology / 2015 / Article / Tab 5

Clinical Study

Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty

Table 5

Characteristics of patients with and without HPG axis suppression (mean ± SD) (range).

CharacteristicHPG axis
Suppressed ()Nonsuppressed ()

Chronological age (years)7.8 ± 1.4 (4.3–9.9)8.6 ± 1.0 (7.0–10.1)0.32
Bone age (years)9.3 ± 2.0 (4.1–11.1)10.6 ± 1.4 (7.8–12.0)0.16
BMI SDS0.8 ± 0.9 (−1.4–1.6)0.9 ± 0.8 (−1.0–3.3)0.95
Basal LH (mIU/mL)1.0 ± 1.2 (0.07–4.6)2.2 ± 3.3 (0.1–10.4)0.005
Peak LH (mIU/mL)9.0 ± 8.9 (3.9–48.8)11.1 ± 10.6 (5.6–27.1)0.44
E2 (pg/mL)26.7 ± 12.9 (3.8–58.5)32.9 ± 24.0 (7.0–68.7)0.00
Leuprolide acetate dose (mg/kg/28 days)0.13 ± 0.14 (0.04–1.12)0.11 ± 0.02 (0.09–0.17)0.47

BMI: body mass index; SDS: standard deviation score.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.